

# Giacomo Laffi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/916982/publications.pdf>

Version: 2024-02-01

124  
papers

8,160  
citations

53794

45  
h-index

48315

88  
g-index

125  
all docs

125  
docs citations

125  
times ranked

7426  
citing authors

#	ARTICLE	IF	CITATIONS
1	Acute viral hepatitis increases liver stiffness values measured by transient elastography. <i>Hepatology</i> , 2008, 47, 380-384.	7.3	643
2	Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. <i>Hepatology</i> , 2007, 45, 1290-1297.	7.3	628
3	Ligands of peroxisome proliferator-activated receptor $\beta$ modulate profibrogenic and proinflammatory actions in hepatic stellate cells. <i>Gastroenterology</i> , 2000, 119, 466-478.	1.3	390
4	Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. <i>Lancet</i> , 2018, 391, 2417-2429.	13.7	345
5	Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. <i>Hepatology</i> , 2005, 42, 1339-1348.	7.3	310
6	Signal Transduction by the Chemokine Receptor CXCR3. <i>Journal of Biological Chemistry</i> , 2001, 276, 9945-9954.	3.4	272
7	Monocyte chemoattractant protein-1 as a chemoattractant for human hepatic stellate cells. <i>Hepatology</i> , 1999, 29, 140-148.	7.3	253
8	Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. <i>Journal of Hepatology</i> , 1999, 30, 639-645.	3.7	235
9	Prevalence of <i>t(14;18)</i> Rearrangement in Patients with Hepatitis C Virus-Related Mixed Cryoglobulinemia with or without B-Cell Lymphomas. <i>Annals of Internal Medicine</i> , 2002, 137, 571.	3.9	185
10	Extracellular signal-regulated kinase activation differentially regulates platelet-derived growth factor's actions in hepatic stellate cells, and is induced by <i>In Vivo</i> liver injury in the rat. <i>Hepatology</i> , 1999, 30, 951-958.	7.3	161
11	Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution. <i>Hepatology</i> , 2013, 58, 65-72.	7.3	159
12	<i>t(14;18)</i> translocation in chronic hepatitis C virus infection. <i>Hepatology</i> , 2000, 31, 474-479.	7.3	157
13	Resistin as an Intrahepatic Cytokine. <i>American Journal of Pathology</i> , 2006, 169, 2042-2053.	3.8	142
14	The chemokine CCL21 modulates lymphocyte recruitment and fibrosis in chronic hepatitis C1 The authors thank Wanda Delogu and Nadia Navari for skillful technical help, Dr. Roberto G. Romanelli for help in collecting liver biopsy specimens, and Dr. Mario Strazzabosco (Ospedali Riuniti di Bergamo,) Tj ETQq0 0.3gBT /Overlock 10 T		
15	Long-term albumin infusion improves survival in patients with cirrhosis and ascites: An unblinded randomized trial. <i>World Journal of Gastroenterology</i> , 2006, 12, 1403.	3.3	128
16	Adenosine monophosphate-activated protein kinase modulates the activated phenotype of hepatic stellate cells. <i>Hepatology</i> , 2008, 47, 668-676.	7.3	118
17	Altered neuro-endocrine-immune pathways in the irritable bowel syndrome: the top-down and the bottom-up model. <i>Journal of Gastroenterology</i> , 2012, 47, 1177-1185.	5.1	114
18	Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. <i>Blood</i> , 2010, 116, 335-342.	1.4	112

#	ARTICLE	IF	CITATIONS
19	Nitrovasodilators inhibit platelet-derived growth factor-induced proliferation and migration of activated human hepatic stellate cells. <i>Gastroenterology</i> , 2000, 119, 479-492.	1.3	108
20	Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study. <i>Hepatology</i> , 2015, 61, 1145-1153.	7.3	107
21	Evidence for a storage pool defect in platelets from cirrhotic patients with defective aggregation. <i>Gastroenterology</i> , 1992, 103, 641-646.	1.3	105
22	Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation. <i>Blood</i> , 2003, 102, 1196-1201.	1.4	99
23	Altered renal and platelet arachidonic acid metabolism in cirrhosis. <i>Gastroenterology</i> , 1986, 90, 274-282.	1.3	98
24	Up-regulated expression of fractalkine and its receptor CX3CR1 during liver injury in humans. <i>Journal of Hepatology</i> , 2002, 37, 39-47.	3.7	97
25	Expression of the thrombin receptor in human liver: Up-regulation during acute and chronic injury. <i>Hepatology</i> , 1998, 27, 462-471.	7.3	95
26	Prevention of severe toxic liver injury and oxidative stress in MCP-1-deficient mice. <i>Journal of Hepatology</i> , 2007, 46, 230-238.	3.7	93
27	Effects of sulindac and ibuprofen in patients with cirrhosis and ascites. <i>Gastroenterology</i> , 1986, 90, 182-187.	1.3	90
28	Under-dilated TIPS Associate With Efficacy and Reduced Encephalopathy in a Prospective, Non-randomized Study of Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1153-1162.e7.	4.4	90
29	Diagnosis, treatment and survival of patients with hepatorenal syndrome: A survey on daily medical practice. <i>Journal of Hepatology</i> , 2011, 55, 1241-1248.	3.7	87
30	Involvement of phosphatidylinositol 3-kinase in the activation of extracellular signal-regulated kinase by PDGF in hepatic stellate cells. <i>FEBS Letters</i> , 1995, 376, 141-145.	2.8	85
31	Altered platelet function in cirrhosis of the liver: Impairment of inositol lipid and arachidonic acid metabolism in response to agonists. <i>Hepatology</i> , 1988, 8, 1620-1626.	7.3	84
32	Curcumin limits the fibrogenic evolution of experimental steatohepatitis. <i>Laboratory Investigation</i> , 2010, 90, 104-115.	3.7	84
33	Increased production of nitric oxide by neutrophils and monocytes from cirrhotic patients with ascites and hyperdynamic circulation. <i>Hepatology</i> , 1995, 22, 1666-1673.	7.3	83
34	Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis. <i>Hepatology</i> , 2001, 34, 19-27.	7.3	81
35	Hepatitis C virus (HCV) infection: A systemic disease. <i>Molecular Aspects of Medicine</i> , 2008, 29, 85-95.	6.4	80
36	Plasma levels of brain natriuretic peptide in patients with cirrhosis. <i>Hepatology</i> , 1992, 16, 156-161.	7.3	78

#	ARTICLE	IF	CITATIONS
37	Agonist-specific regulation of monocyte chemoattractant protein-1 expression by cyclooxygenase metabolites in hepatic stellate cells. <i>Hepatology</i> , 2001, 33, 713-721.	7.3	69
38	Renal hemodynamic and natriuretic effects of human atrial natriuretic factor infusion in cirrhosis with ascites. <i>Gastroenterology</i> , 1989, 96, 167-177.	1.3	67
39	Tyrosine phosphorylation of focal adhesion kinase by PDGF is dependent on Ras in human hepatic stellate cells. <i>Hepatology</i> , 2000, 31, 131-140.	7.3	67
40	Defective signal transduction in platelets from cirrhotics is associated with increased cyclic nucleotides. <i>Gastroenterology</i> , 1993, 105, 148-156.	1.3	62
41	The integrin, $\alpha_6\beta_1$ , is necessary for the matrix-dependent activation of FAK and MAP kinase and the migration of human hepatocarcinoma cells. <i>Hepatology</i> , 2001, 34, 42-49.	7.3	59
42	Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: Role of polymorphic variants of BAFF promoter and Fc $\gamma$ 3 receptors. <i>Arthritis and Rheumatism</i> , 2011, 63, 1446-1451.	6.7	59
43	Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: A prospective, controlled pilot study. <i>Digestive and Liver Disease</i> , 2014, 46, 833-837.	0.9	57
44	Transjugular intrahepatic portosystemic shunt (TIPS): current indications and strategies to improve the outcomes. <i>Internal and Emergency Medicine</i> , 2020, 15, 37-48.	2.0	50
45	Prevalence of mixed infection by different hepatitis C virus genotypes in patients with hepatitis C virus-related chronic liver disease. <i>Translational Research</i> , 1999, 134, 68-73.	2.3	47
46	Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C. <i>Digestive and Liver Disease</i> , 2013, 45, 840-843.	0.9	47
47	Apparent hepatitis B virus infection and hepatitis C virus replication in alcoholic subjects with and without liver disease. <i>Hepatology</i> , 1994, 19, 577-582.	7.3	44
48	Altered furosemide pharmacokinetics in chronic alcoholic liver disease with ascites contributes to diuretic resistance. <i>Gastroenterology</i> , 1987, 92, 294-298.	1.3	43
49	Comparison of the effects of torasemide and furosemide in nonazotemic cirrhotic patients with ascites: A randomized, double-blind study. <i>Hepatology</i> , 1991, 13, 1101-1105.	7.3	43
50	Biosynthesis of platelet-activating factor and its 1O-acyl analogue by liver fat-storing cells. <i>Gastroenterology</i> , 1994, 106, 1301-1311.	1.3	43
51	Knockout of $\alpha_6\beta_1$ -integrin expression reverses the transformed phenotype of hepatocarcinoma cells. <i>Gastroenterology</i> , 1998, 115, 433-442.	1.3	43
52	Cardiovascular and renal function in normotensive and hypertensive patients with compensated cirrhosis: effects of posture. <i>Journal of Hepatology</i> , 1999, 30, 632-638.	3.7	42
53	The hepatitis C virus infection as a systemic disease. <i>Internal and Emergency Medicine</i> , 2012, 7, 201-208.	2.0	42
54	Role of MicroRNA Profile Modifications in Hepatitis C Virus-Related Mixed Cryoglobulinemia. <i>PLoS ONE</i> , 2013, 8, e62965.	2.5	42

#	ARTICLE	IF	CITATIONS
55	Immediate effects of furosemide on renal hemodynamics in chronic liver disease with ascites. <i>Gastroenterology</i> , 1987, 92, 1859-1863.	1.3	41
56	Sulindac and Indomethacin Suppress the Diuretic Action of Furosemide in Patients With Cirrhosis and Ascites: Evidence That Sulindac Affects Renal Prostaglandins. <i>American Journal of Kidney Diseases</i> , 1985, 6, 217-221.	1.9	39
57	Autonomic Regulation of Heart Rate and QT Interval in Nonalcoholic Cirrhosis with Ascites. <i>Digestion</i> , 1997, 58, 580-586.	2.3	39
58	Cerebral autoregulation in patients with cirrhosis and ascites. <i>Journal of Hepatology</i> , 1997, 27, 114-120.	3.7	38
59	On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. <i>Journal of Hepatology</i> , 2021, 74, 340-349.	3.7	38
60	Effects of OKY 046, a thromboxane-synthase inhibitor, on renal function in nonazotemic cirrhotic patients with ascites. <i>Gastroenterology</i> , 1988, 94, 1470-1477.	1.3	34
61	Defective aggregation in cirrhosis is independent of in vivo platelet activation. <i>Journal of Hepatology</i> , 1996, 24, 436-443.	3.7	34
62	HCV patients, psychopathology and tryptophan metabolism: analysis of the effects of pegylated interferon plus ribavirin treatment. <i>Digestive and Liver Disease</i> , 2007, 39, S107-S111.	0.9	30
63	Performance of Doppler ultrasound in the prediction of severe portal hypertension in hepatitis C virus-related chronic liver disease. <i>Liver International</i> , 2007, 27, 1379-1388.	3.9	29
64	Neuroendocrine markers and psychological features in patients with irritable bowel syndrome. <i>International Journal of Colorectal Disease</i> , 2013, 28, 1203-1208.	2.2	28
65	Torsemide in the treatment of patients with cirrhosis and ascites. <i>Cardiovascular Drugs and Therapy</i> , 1993, 7, 81-85.	2.6	26
66	Blunted natriuretic response to low-dose brain natriuretic peptide infusion in nonazotemic cirrhotic patients with ascites and avid sodium retention. <i>Hepatology</i> , 1995, 22, 1745-1750.	7.3	26
67	Increased Plasma Carbon Monoxide in Patients With Viral Cirrhosis and Hyperdynamic Circulation. <i>American Journal of Gastroenterology</i> , 2009, 104, 891-897.	0.4	26
68	Can BAFF promoter polymorphism be a predisposing condition for HCV-related mixed cryoglobulinemia?. <i>Blood</i> , 2008, 112, 4353-4354.	1.4	25
69	Renal Functional Impairment and Sodium Retention in Liver Cirrhosis. <i>Digestion</i> , 1989, 43, 1-32.	2.3	24
70	Association between persistent lymphatic infection by hepatitis C virus after antiviral treatment and mixed cryoglobulinemia. <i>Blood</i> , 2008, 111, 2943-2945.	1.4	24
71	Non-invasive assessment of liver fibrosis in patients with HBV-related chronic liver disease undergoing antiviral treatment: A preliminary study. <i>European Journal of Pharmacology</i> , 2017, 806, 105-109.	3.5	24
72	Neuroendocrine Dysregulation in Irritable Bowel Syndrome Patients: A Pilot Study. <i>Journal of Neurogastroenterology and Motility</i> , 2017, 23, 428-434.	2.4	24

#	ARTICLE	IF	CITATIONS
73	Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib. <i>World Journal of Gastroenterology</i> , 2014, 20, 786.	3.3	24
74	Pathophysiology and treatment of ascites and the hepatorenal syndrome. <i>Bailliere's Clinical Gastroenterology</i> , 1992, 6, 581-607.	0.9	23
75	Effects of dietary supplementation with arachidonic acid on platelet and renal function in patients with cirrhosis. <i>Clinical Science</i> , 2004, 106, 27-34.	4.3	23
76	Ascites and hepatorenal syndrome during cirrhosis: two entities or the continuation of the same complication?. <i>Journal of Hepatology</i> , 1999, 31, 1087.	3.7	22
77	Pharmacokinetics and pharmacodynamics of torasemide and furosemide in patients with diuretic resistant ascites. <i>Journal of Hepatology</i> , 1996, 25, 481-490.	3.7	21
78	Cardiovascular effects of canrenone in patients with preascitic cirrhosis. <i>Hepatology</i> , 2002, 35, 1441-1448.	7.3	21
79	Assay methods for 6-keto-prostaglandin F <sub>1</sub> ± in human urine. <i>Biomedical Applications</i> , 1985, 339, 1-9.	1.7	19
80	Thrombopoietin stimulates migration and activates multiple signaling pathways in hepatoblastoma cells. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 290, G120-G128.	3.4	19
81	Noncontrast Functional MRI of the Kidneys. <i>Current Urology Reports</i> , 2012, 13, 99-107.	2.2	19
82	Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab. <i>Digestive and Liver Disease</i> , 2007, 39, S129-S133.	0.9	18
83	Diffusion-Weighted Imaging of the Liver: A Comprehensive Review. <i>Current Problems in Diagnostic Radiology</i> , 2013, 42, 77-83.	1.4	18
84	Thromboxane-receptor blockade increases water diuresis in cirrhotic patients with ascites. <i>Gastroenterology</i> , 1992, 103, 1017-1021.	1.3	17
85	ω polyunsaturated fatty acids worsen inflammation and fibrosis in experimental nonalcoholic steatohepatitis. <i>Liver International</i> , 2014, 34, 918-930.	3.9	17
86	Molecular mechanism underlying impaired platelet responsiveness in liver cirrhosis. <i>FEBS Letters</i> , 1987, 220, 217-219.	2.8	16
87	Intrarenal thromboxane A <sub>2</sub> generation reduces the furosemide-induced sodium and water diuresis in cirrhosis with ascites. <i>Gastroenterology</i> , 1988, 95, 1081-1087.	1.3	16
88	Tumor response of temozolomide in combination with morphine in a xenograft model of human glioblastoma. <i>Oncotarget</i> , 2017, 8, 89595-89606.	1.8	16
89	Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment. <i>Journal of Translational Medicine</i> , 2014, 12, 21.	4.4	14
90	Impaired sympathetic regulation of cerebral blood flow in patients with cirrhosis of the liver. <i>Clinical Science</i> , 2002, 103, 43-51.	4.3	13

#	ARTICLE	IF	CITATIONS
91	Effects of supplementation with unsaturated fatty acids on plasma and membrane lipid composition and platelet function in patients with cirrhosis and defective aggregation. <i>Journal of Hepatology</i> , 1998, 28, 654-661.	3.7	12
92	Thrombocytopenia in chronic liver disease: Lessons from transplanted patients. <i>Journal of Hepatology</i> , 2007, 47, 625-629.	3.7	12
93	Systemic haemodynamics, renal and platelet function during chronic propranolol administration in patients with compensated cirrhosis. <i>Liver</i> , 1987, 7, 110-115.	0.1	12
94	Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: A prospective pilot study. <i>World Journal of Gastroenterology</i> , 2015, 21, 3013.	3.3	12
95	Effects of repeated atrial natriuretic peptide bolus injections in cirrhotic patients with refractory ascites. <i>Liver</i> , 1989, 9, 315-321.	0.1	11
96	Effect of chronic hepatitis C virus infection on inflammatory lipid mediators. <i>Digestive and Liver Disease</i> , 2007, 39, S76-S82.	0.9	10
97	Screening of distress among hospitalized patients in a department of internal medicine. <i>Asian Journal of Psychiatry</i> , 2015, 18, 91-96.	2.0	10
98	Aldoxorubicin and Temozolomide combination in a xenograft mice model of human glioblastoma. <i>Oncotarget</i> , 2018, 9, 34935-34944.	1.8	10
99	Systemic Hemodynamics and Renal Function in Cirrhotic Patients during Plasma Volume Expansion. <i>Digestion</i> , 1983, 27, 138-145.	2.3	9
100	Acute on chronic liver failure: From pathophysiology to clinical management. <i>Trends in Anaesthesia and Critical Care</i> , 2013, 3, 122-129.	0.9	9
101	Serotonin and its implication in the side-effects of interferon-based treatment of patients with chronic viral hepatitis: Pharmacological interventions. <i>Hepatology Research</i> , 2014, 44, 9-16.	3.4	9
102	Assessment of liver fibrosis in primary biliary cholangitis: Comparison between indirect serum markers and fibrosis morphometry. <i>Digestive and Liver Disease</i> , 2016, 48, 298-301.	0.9	9
103	Super-Resolution Microscopy Reveals an Altered Fibrin Network in Cirrhosis: The Key Role of Oxidative Stress in Fibrinogen Structural Modifications. <i>Antioxidants</i> , 2020, 9, 737.	5.1	9
104	Complications of cirrhosis: is endothelium guilty?. <i>Journal of Hepatology</i> , 1999, 30, 532-535.	3.7	8
105	Point and interval estimations of circadian melatonin ecphasia in Smith-Magenis syndrome. <i>Biomedicine and Pharmacotherapy</i> , 2003, 57, 31-34.	5.6	8
106	Effect of some cyclooxygenase inhibitors on the increase in guanosine 3',5'-cyclic monophosphate induced by NO-donors in human whole platelets. <i>British Journal of Pharmacology</i> , 1998, 123, 1457-1463.	5.4	6
107	Impaired sympathetic regulation of cerebral blood flow in patients with cirrhosis of the liver. <i>Clinical Science</i> , 2002, 103, 43.	4.3	6
108	Dysregulated Intrahepatic CD4+ T-Cell Activation Drives Liver Inflammation in Ileitis-Prone SAMP1/YitFc Mice. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2015, 1, 406-419.	4.5	6

#	ARTICLE	IF	CITATIONS
109	Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Liver Cancer</i> , 2021, 10, 126-136.	7.7	6
110	Elevated plasma levels of urotensin II do not correlate with systemic haemodynamics in patients with cirrhosis. <i>Digestive and Liver Disease</i> , 2011, 43, 314-318.	0.9	5
111	Complete resolution of primary sclerosing peritonitis ("abdominal cocoon") following long term therapy for <i>Tropheryma whipplei</i> : a case report and review of literature. <i>BMJ Case Reports</i> , 2009, 2009, bcr0420091810-bcr0420091810.	0.5	5
112	Altered clot formation and lysis are associated with increased fibrinolytic activity in ascites in patients with advanced cirrhosis. <i>Internal and Emergency Medicine</i> , 2021, 16, 339-347.	2.0	4
113	Epidemiological, demographic and clinical data on chronic viral hepatitis C in Tuscany. <i>Current Medical Research and Opinion</i> , 2019, 35, 661-666.	1.9	3
114	Clinical epidemiology of chronic viral hepatitis B: A Tuscany real-word large-scale cohort study. <i>World Journal of Hepatology</i> , 2018, 10, 409-416.	2.0	3
115	Macro-aspartate aminotransferase in a healthy woman. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 378-381.	8.9	3
116	Hepato-systemic gradient of carbon monoxide in cirrhosis. <i>European Journal of Internal Medicine</i> , 2012, 23, e14-e18.	2.2	2
117	Atrial Natriuretic Peptide and Other Natriuretic Factors in Cirrhosis. , 0, , 73-83.		2
118	DRESS syndrome in a patient with chronic hepatic encephalopathy. <i>Turkish Journal of Gastroenterology</i> , 2016, 27, 391-394.	1.1	2
119	Paradoxical embolization in TIPS: take a closer look to the heart. <i>Annals of Hepatology</i> , 2015, 14, 127-31.	1.5	2
120	Vasoactive factors in the mechanism of renal sodium handling in cirrhotics: The effect of acute plasma expansion. <i>Pharmacological Research Communications</i> , 1984, 16, 613-635.	0.2	1
121	Transjugular Intrahepatic Portosystemic Shunt does not affect the efficacy and safety of direct-acting antivirals in patients with advanced cirrhosis: A real-life, case-control study. <i>Digestive and Liver Disease</i> , 2019, 51, 870-874.	0.9	1
122	Characterization of lymphocyte subsets in ascitic fluid and peripheral blood of decompensated cirrhotic patients with chronic hepatitis C and alcoholic liver disease: A pivotal study. <i>International Journal of Immunopathology and Pharmacology</i> , 2020, 34, 205873842092958.	2.1	1
123	Non invasive continuous hemodynamic evaluation of cirrhotic patients after postural challenge. <i>World Journal of Hepatology</i> , 2012, 4, 149.	2.0	0
124	Treatment of Ascites in Cirrhosis. , 1996, , 286-295.		0